Global Blood Therapeutics (GBT:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry
Key Findings
This unique new report provides deep financial benchmarks for Global Blood Therapeutics (GBT:NAS) compared to its top competitors and compared to the average for all companies within its primary industry. – This benchmarking study for Global Blood Therapeutics (GBT:NAS) includes growth forecast for its primary industry for the current year and the next 7 years. The purpose of this report is to provide vital corporate-specific benchmarks, comparing the Subject Company to its top competitors (on a company-by-company basis) and to the averages within its primary industry for all key metrics. This is a unique report containing high-value data. The report begins with a superb overview of the primary industry of the Subject Company, including historical industry revenues, revenue forecasts and CAGR. Then the report moves into industry averages and metrics, then into data specific to the Subject Company, with comparative data for the Subject Company's top competitors. This report will save countless hours of research and analytical work for the end user.Core Benefits:
1) Comprehensive benchmarks for the Subject Company:a. Benchmarked against the leading firms in its primary industry
b. Benchmarked against the average for publicly-held companies (U.S.) in its industry.
c. This includes financial results, ratios, operating/financial statements and metrics in one package, including both the latest year and 6 most-recent historical years.
2) A snapshot overview of the company's primary industry, including current and historic revenues and employment, along with a long term forecast for industry growth, with CAGR (compound annual growth rate), employee population and much more.
3) Detailed rankings of the Subject Company against top companies within the industry (U.S.-based firms) for key items including:
a. Approximate market capitalization
b. Employees
c. Revenues
d. Net income
e. 3-Year revenue growth (%)
f. 3-Year income growth (%)
g. Return on assets (%)
h. Return on equity (%)
i. Return on invested capital (%)
4) Leading competitors’ profiles. Approximately 70 pages in length. Approximately 28 Charts. The region is the USA. This report is part of the Corporate Benchmarks series. The publisher has unique capabilities for creating corporate and industry information, due to research that we have been conducting for more than 20 years. Our access to hundreds of industry tables from our own databases, along with our databases of public and private company information, industry trends analysis and other resources, have been utilized in preparing this report. Similar reports are available for all significant, U.S. publicly-held firms. Designed to benefit: Investment Firms, Private Equity, Hedge Funds, Lenders, Appraisers and Consultants.
Table of Contents
I. Introduction
II. Industry Analysis Summary of the Subject Company's Primary Industry
III. Industry Revenues, Historical and Projected
IV. Comparative Financial Benchmarks for the Subject Company by Industry Averages in a 6-year Time Series of Detailed Financials
V. Competitive Summary of Top Companies Within the Industry, Profiles & Ranks
Executive Summary
The purpose of this report is to provide vital benchmarking of KPIs and financial metrics of this company to its industry peers and competitors. This includes benchmarks and histories for all income statements, balance sheets and cash flow items. In addition, we provide an industry-specific market overview for this firm’s primary sector, within the United States, with an emphasis on market sizing and industry growth. This includes a unique 8-year history and 8-year forward projections of market sizing. While other firms may publish company- and industry-specific data and forecasts, we believe that such efforts produce limited and often inaccurate results.The publisher has unique capabilities for creating industry information, due to the industry research that Plunkett has been conducting for more than 30 years. The publisher's access to hundreds of industry tables from data sets, along with databases of public and private company information, proprietary industry trends analysis and other resources, have been utilized fully in preparing this report.
Companies Mentioned
- Abbott Laboratories
- AbbVie Inc
- Amgen Inc
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Genentech Inc
- Gilead Sciences Inc
- Johnson & Johnson
- Merck & Co Inc
- Pfizer Inc
Methodology
The data development evolved from research methods originally established by the founder of the company.
Through the years, a research methodology evolved based on strict guidelines used to build and maintain the content of six proprietary business and industry databases:
- An industry trends database
- An industry statistics database
- Industry Analytics (deep financial data for hundreds of Industry codes)
- A leading companies database
- A business and industry glossary database
- An industry associations and professional societies database
- Analysts are trained to follow research formulas and methodology. They use company-approved sources in their work and post their findings daily to proprietary databases. All research results go through multi-step editing processes. And, all results are date-stamped.
- Internal research, analysis, fact-checking and data gathering by the Research staff.
- Over 3,500 industry associations, professional societies and government agencies worldwide with which the publisher maintains relationships and/or from which they obtain industry-specific/country-specific data.
- Financial analysts, industry executives and industry experts with whom the publisher maintains communications.
- Corporate disclosure documents and financial statements.
- Industry conference proceedings.
- Analysis of white papers, reports, periodicals and publications.
- Multiple proprietaries, government, industry and financial databases developed by the publisher.
LOADING...
